BioSpace News Archive

Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 3,883,036 common shares at a purchase price of US$2.97375 per common share in a registered direct offering (the “Offering”) priced at-the-market under Nasdaq rules for aggregate gross proceeds to the Company of

Noveome Biotherapeutics Announces Positive Data for Phase 2 Clinical Trial of ST266 in Patients with Persistent Corneal Epithelial Defect s Noveome to conduct Phase 2b trial of ST266 in Persistent Corneal Epithelial Defects

As facilities and establishments continue to open across the country, there will be no returning to “normal”. COVID-19 has altered our standards for health and safety and with that, procedures have been put in place specific to each industry.

Pharmaceutical Executive ® Reveals 20th Annual Pharma 50 for 2020 The listing features the top 50 biopharma companies by 2019 prescription sales

The National Association of Specialty Pharmacy (NASP), a nonprofit organization representing all specialty pharmacy industry stakeholders, announces that this year’s Annual Meeting & Expo will be transitioning to a virtual conference EXPERIENCE.

In lieu of a daily in-person update to the media, Dr. Theresa Tam, Canada’s Chief Public Health Officer, issued the following statement

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that a post hoc analysis of the Phase 3 RESET study evaluating the efficacy of rivipansel , its wholly-owned development candidate, in acute vaso-occlusive crisis (VOC) shows that patients treated with rivipansel within approximately 26 hours of the onset of pain in their crisis experienced statistically significant improvements in the primary efficacy endpoint of time to readiness for discharge compared to placeb

Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) today provides an update on the Company’s voluntary liquidation process (the “Liquidation”) that started on January 16, 2020 (the “Effective Date”).

Today, the U.S. Food and Drug Administration approved Tivicay (dolutegravir) tablets and Tivicay PD (dolutegravir) tablets for suspension to treat HIV-1 infection in pediatric patients at least four weeks old and weighing at least 3 kg (6.61 pounds) in combination with other antiretroviral treatments.

Johnson & Johnson Consumer Health* today presented findings from the longest longitudinal study of infant and mother skin microbiome research at the American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2020, from June 12 – 14, 2020.